Positive 1b Data For Mastocytosis Therapy Announced By Major Biotech Company
Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to develop effective treatments for this rare and complex disorder. $Cogent Biosciences (COGT.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
